Novel Capsid Inhibitor Approved for Super-Refractory HIV
The FDA approved lenacapavir (Sunlenca) in combination with antiretroviral therapy (ART) for heavily pretreated HIV-1 patients with drug-resistant infections, and for those who cannot tolerate other available options. Lenacapavir, a first-in-class long-acting HIV capsid inhibitor, is initially administered via oral tablets (300 mg) and subcutaneous shots (463.5 mg/1.5 mL), which are then followed by maintenance […]
Adagrasib Shows Anti-Tumor Activity in Heavily Pretreated KRAS-Mutant CRC
Adagrasib (Krazati) demonstrated antitumor activity in heavily pretreated patients with KRAS G12C-mutated, metastatic colorectal cancer (CRC), according to phase I/II study results. Monotherapy with the oral KRAS inhibitor led to responses in 19% (95% CI 8-33) of 43 evaluable patients with CRC, with a median duration of response of 4.3 months (95% CI 2.3-8.3) and […]